Lilly Leans Into Hearing Loss In $1.12B+ Gene Editing Pact With Seamless

By /

The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.

Scroll to Top